Yield10 brings unique capabilities in advanced metabolic engineering and systems biology to optimize photosynthesis and carbon efficiency in crops to increase grain or biomass yield. The commercial plan is based on establishing a grain contracting business leveraging proprietary elite Camelina seed varieties, focusing on low-carbon intensity feedstock oil for biofuels and omega-3 oils for nutritional applications. On December 6, 2024, Yield10 Bioscience filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Cyborg Score Rationale
Yield10 filed for Chapter 11 bankruptcy in December 2024, indicating severe financial distress. The company has only ~29 employees as of February 2026 and is still in bankruptcy proceedings. While the underlying technology for crop improvement has potential, the company's ability to execute and commercialize remains highly uncertain.
Top Insights
Chapter 11 bankruptcy filed December 2024 - company in restructuring mode with uncertain viability
Minimal revenue generation as of Q2 2024 ($450k quarterly); substantial ongoing operating losses (~$3.2M net loss in Q2 2024)
Camelina oilseed platform positioned for multiple market applications: renewable fuels, omega-3 nutrition, and future bioplastics
Strategic pivot to licensing and partnerships (VISION Bioenergy deal) suggests asset monetization over direct commercialization
Named Competitors
Monsanto/Bayer CropScience — Global leader in GMO seeds, crop protection, and agricultural biotech
Corteva Agriscience Seeds & Traits — Major crop genetics, seeds, and trait development